Mesenchymal stroma cells

for treatment of steroid-refractory acute GvHD

Acute graft-versus-host disease is still a major complication after allogeneic stem cell transplantation, especially when conventional therapy options fail. In steroid-refractory acute graft-versus-host disease, mesenchymal stromal cells and their immunomodulatory properties have shown to be an effective treatment option.

In our center, we have developed a method of generating standardized MSC preparations from pooled bone marrow mononuclear cells of 8 different donors, which are characterized by a consistent and reproducible effectiveness (MSC-FFM). In cooperation with the German Blood Transfusion Service / Institute of Transfusion Medicine and Immunohematology of the Johann Wolfgang Goethe University, we have succeeded in establishing a mesenchymal stem cell bank of these preparations under GMP conditions. A drug approval according to  § 4b AMG and an out-licensing to a pharmaceutical company could be achieved.